# Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

> **NCT03447470** · PHASE1 · COMPLETED · sponsor: **Redx Pharma Ltd** · enrollment: 46 (actual)

## Conditions studied

- Cancer
- Solid Tumor

## Interventions

- **DRUG:** RXC004
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03447470
- **Lead sponsor:** Redx Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-09-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03447470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03447470, "Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03447470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*